Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels
This article was originally published in The Pink Sheet Daily
Executive Summary
While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has focused on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use that as a template for future free trade agreements.
You may also be interested in...
Biologics Exclusivity: GPhA Making Last Stand Against TPP
The U.S. Generic Pharmaceutical Association and other groups are opposing the Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.
Biologics Exclusivity: GPhA Making Last Stand In Pacific
GPhA, AARP oppose Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.
Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report
The failure of U.S. trading partners to adequately protect pharmaceutical test data remains one of the top concerns of the United States Trade Representative in its 2011 Special 301 Report on intellectual property rights